MRSA sepsis in patients with hematological malignancies: Importance of early administration of intravenous vancomycin

M. Yoshida, M. Ito, T. Izumi, H. Kurata, S. Tsunoda, Y. Hosino, S. Okada, J. Tsunoda, S. Imagawa, T. Suzuki, N. Komatsu, K. Muroi, K. Hatake, A. Miwa, T. Suda, S. Sakamoto, M. Hayashi, Y. Miura

Research output: Contribution to journalArticle

Abstract

From 1985 to 1991, MRSA sepsis was identified in 18 patients with hematological malignancies. The mortality rate was 55.6% (10/18), and the presence of DIC was significantly associated with high mortality (p = 0.02). In addition to the use of standard empiric therapy, vancomycin was intravenously administered to 10 patients. The daily dose of 1.5 g was divided into 3 times, and was administered in 60-minute infusions. Patients 60 years of age or older received a daily dose of 1.0 g. The prognosis of 6 patients who received vancomycin within 4 days of the onset of sepsis was significantly better than that of 4 patients who received it 4 or more days after the onset of sepsis and that of 8 patients who did not receive it (mortality was 1/6 vs. 9/12; p = 0.04). As for the side effects, liver dysfunction was observed in 5 patients and renal dysfunction was observed in 3 patients. The administration of VCM was discontinued in one of the former and was continued at a reduced dose in one of the latter. Because of the severity of the illness and the lack of effective drugs, we concluded that vancomycin is a highly useful drug for the treatment of MRSA sepsis in patients with hematological malignancies.

Original languageEnglish
Pages (from-to)976-980
Number of pages5
JournalChemotherapy
Volume42
Issue number8
Publication statusPublished - 1994

Fingerprint

Hematologic Neoplasms
Vancomycin
Methicillin-Resistant Staphylococcus aureus
Intravenous Administration
Sepsis
Mortality
Dacarbazine
Pharmaceutical Preparations
Liver Diseases
Kidney
Therapeutics

ASJC Scopus subject areas

  • Pharmacology

Cite this

Yoshida, M., Ito, M., Izumi, T., Kurata, H., Tsunoda, S., Hosino, Y., ... Miura, Y. (1994). MRSA sepsis in patients with hematological malignancies: Importance of early administration of intravenous vancomycin. Chemotherapy, 42(8), 976-980.

MRSA sepsis in patients with hematological malignancies : Importance of early administration of intravenous vancomycin. / Yoshida, M.; Ito, M.; Izumi, T.; Kurata, H.; Tsunoda, S.; Hosino, Y.; Okada, S.; Tsunoda, J.; Imagawa, S.; Suzuki, T.; Komatsu, N.; Muroi, K.; Hatake, K.; Miwa, A.; Suda, T.; Sakamoto, S.; Hayashi, M.; Miura, Y.

In: Chemotherapy, Vol. 42, No. 8, 1994, p. 976-980.

Research output: Contribution to journalArticle

Yoshida, M, Ito, M, Izumi, T, Kurata, H, Tsunoda, S, Hosino, Y, Okada, S, Tsunoda, J, Imagawa, S, Suzuki, T, Komatsu, N, Muroi, K, Hatake, K, Miwa, A, Suda, T, Sakamoto, S, Hayashi, M & Miura, Y 1994, 'MRSA sepsis in patients with hematological malignancies: Importance of early administration of intravenous vancomycin', Chemotherapy, vol. 42, no. 8, pp. 976-980.
Yoshida M, Ito M, Izumi T, Kurata H, Tsunoda S, Hosino Y et al. MRSA sepsis in patients with hematological malignancies: Importance of early administration of intravenous vancomycin. Chemotherapy. 1994;42(8):976-980.
Yoshida, M. ; Ito, M. ; Izumi, T. ; Kurata, H. ; Tsunoda, S. ; Hosino, Y. ; Okada, S. ; Tsunoda, J. ; Imagawa, S. ; Suzuki, T. ; Komatsu, N. ; Muroi, K. ; Hatake, K. ; Miwa, A. ; Suda, T. ; Sakamoto, S. ; Hayashi, M. ; Miura, Y. / MRSA sepsis in patients with hematological malignancies : Importance of early administration of intravenous vancomycin. In: Chemotherapy. 1994 ; Vol. 42, No. 8. pp. 976-980.
@article{11a5eeee336a4967a8325aa4cc29a7c1,
title = "MRSA sepsis in patients with hematological malignancies: Importance of early administration of intravenous vancomycin",
abstract = "From 1985 to 1991, MRSA sepsis was identified in 18 patients with hematological malignancies. The mortality rate was 55.6{\%} (10/18), and the presence of DIC was significantly associated with high mortality (p = 0.02). In addition to the use of standard empiric therapy, vancomycin was intravenously administered to 10 patients. The daily dose of 1.5 g was divided into 3 times, and was administered in 60-minute infusions. Patients 60 years of age or older received a daily dose of 1.0 g. The prognosis of 6 patients who received vancomycin within 4 days of the onset of sepsis was significantly better than that of 4 patients who received it 4 or more days after the onset of sepsis and that of 8 patients who did not receive it (mortality was 1/6 vs. 9/12; p = 0.04). As for the side effects, liver dysfunction was observed in 5 patients and renal dysfunction was observed in 3 patients. The administration of VCM was discontinued in one of the former and was continued at a reduced dose in one of the latter. Because of the severity of the illness and the lack of effective drugs, we concluded that vancomycin is a highly useful drug for the treatment of MRSA sepsis in patients with hematological malignancies.",
author = "M. Yoshida and M. Ito and T. Izumi and H. Kurata and S. Tsunoda and Y. Hosino and S. Okada and J. Tsunoda and S. Imagawa and T. Suzuki and N. Komatsu and K. Muroi and K. Hatake and A. Miwa and T. Suda and S. Sakamoto and M. Hayashi and Y. Miura",
year = "1994",
language = "English",
volume = "42",
pages = "976--980",
journal = "Chemotherapy",
issn = "0009-3165",
publisher = "S. Karger AG",
number = "8",

}

TY - JOUR

T1 - MRSA sepsis in patients with hematological malignancies

T2 - Importance of early administration of intravenous vancomycin

AU - Yoshida, M.

AU - Ito, M.

AU - Izumi, T.

AU - Kurata, H.

AU - Tsunoda, S.

AU - Hosino, Y.

AU - Okada, S.

AU - Tsunoda, J.

AU - Imagawa, S.

AU - Suzuki, T.

AU - Komatsu, N.

AU - Muroi, K.

AU - Hatake, K.

AU - Miwa, A.

AU - Suda, T.

AU - Sakamoto, S.

AU - Hayashi, M.

AU - Miura, Y.

PY - 1994

Y1 - 1994

N2 - From 1985 to 1991, MRSA sepsis was identified in 18 patients with hematological malignancies. The mortality rate was 55.6% (10/18), and the presence of DIC was significantly associated with high mortality (p = 0.02). In addition to the use of standard empiric therapy, vancomycin was intravenously administered to 10 patients. The daily dose of 1.5 g was divided into 3 times, and was administered in 60-minute infusions. Patients 60 years of age or older received a daily dose of 1.0 g. The prognosis of 6 patients who received vancomycin within 4 days of the onset of sepsis was significantly better than that of 4 patients who received it 4 or more days after the onset of sepsis and that of 8 patients who did not receive it (mortality was 1/6 vs. 9/12; p = 0.04). As for the side effects, liver dysfunction was observed in 5 patients and renal dysfunction was observed in 3 patients. The administration of VCM was discontinued in one of the former and was continued at a reduced dose in one of the latter. Because of the severity of the illness and the lack of effective drugs, we concluded that vancomycin is a highly useful drug for the treatment of MRSA sepsis in patients with hematological malignancies.

AB - From 1985 to 1991, MRSA sepsis was identified in 18 patients with hematological malignancies. The mortality rate was 55.6% (10/18), and the presence of DIC was significantly associated with high mortality (p = 0.02). In addition to the use of standard empiric therapy, vancomycin was intravenously administered to 10 patients. The daily dose of 1.5 g was divided into 3 times, and was administered in 60-minute infusions. Patients 60 years of age or older received a daily dose of 1.0 g. The prognosis of 6 patients who received vancomycin within 4 days of the onset of sepsis was significantly better than that of 4 patients who received it 4 or more days after the onset of sepsis and that of 8 patients who did not receive it (mortality was 1/6 vs. 9/12; p = 0.04). As for the side effects, liver dysfunction was observed in 5 patients and renal dysfunction was observed in 3 patients. The administration of VCM was discontinued in one of the former and was continued at a reduced dose in one of the latter. Because of the severity of the illness and the lack of effective drugs, we concluded that vancomycin is a highly useful drug for the treatment of MRSA sepsis in patients with hematological malignancies.

UR - http://www.scopus.com/inward/record.url?scp=0027981371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027981371&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0027981371

VL - 42

SP - 976

EP - 980

JO - Chemotherapy

JF - Chemotherapy

SN - 0009-3165

IS - 8

ER -